Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aquestive Therapeutics Inc (AQST)

Aquestive Therapeutics Inc (AQST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 490,621
  • Shares Outstanding, K 122,045
  • Annual Sales, $ 44,550 K
  • Annual Income, $ -83,780 K
  • EBIT $ -71 M
  • EBITDA $ -60 M
  • 60-Month Beta 1.61
  • Price/Sales 11.34
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 77.25% (-6.26%)
  • Historical Volatility 50.20%
  • IV Percentile 1%
  • IV Rank 0.77%
  • IV High 382.65% on 06/16/25
  • IV Low 74.88% on 02/27/26
  • Expected Move (DTE 19) 0.48 (12.05%)
  • Put/Call Vol Ratio 2.02
  • Today's Volume 148
  • Volume Avg (30-Day) 1,483
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 49,136
  • Open Int (30-Day) 57,501
  • Expected Range 3.54 to 4.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.14
  • Number of Estimates 5
  • High Estimate -0.12
  • Low Estimate -0.21
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +41.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.77 +6.73%
on 03/24/26
4.50 -10.67%
on 03/05/26
+0.02 (+0.50%)
since 02/27/26
3-Month
2.93 +37.20%
on 01/30/26
6.59 -39.00%
on 01/02/26
-1.97 (-32.89%)
since 12/26/25
52-Week
2.12 +89.62%
on 05/13/25
7.55 -46.75%
on 10/20/25
+0.81 (+25.23%)
since 03/27/25

Most Recent Stories

More News
AQST DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics Investors of Securities Class Action Deadline on May 4, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their Options

AQST : 4.02 (-2.90%)
AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK , March 27, 2026 /PRNewswire/ --

AQST : 4.02 (-2.90%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - AQST

NEW YORK , March 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST).  ...

AQST : 4.02 (-2.90%)
AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallSt

Disclosure Under Scrutiny: Were Risk Warnings Adequate for Aquestive's Anaphylm NDA?

AQST : 4.02 (-2.90%)
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: Levi & Korsinsky

Wall Street Reassessment: Analyst Opinion Evolution on AQST

AQST : 4.02 (-2.90%)
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Claims CEO Allegedly Misrepresented Company Prospects: Levi & Korsinsky

Important Information Regarding Section 20(a) Individual Liability Claims

AQST : 4.02 (-2.90%)
AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm

NEW YORK , March 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST).

AQST : 4.02 (-2.90%)
Robbins LLP Urges AQST Stockholders Who Lost Money Investing in Aquestive Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action

SAN DIEGO , March 23, 2026 /PRNewswire/ -- Robbins LLP  reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aquestive Therapeutics,...

AQST : 4.02 (-2.90%)
AQST DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their Options

AQST : 4.02 (-2.90%)
Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer

Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal Officer and Chief Compliance Officer effective April 2, 2026 Lori J. Braender to remain in a non-executive role as Corporate Secretary...

AQST : 4.02 (-2.90%)

Business Summary

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based...

See More

Key Turning Points

3rd Resistance Point 4.25
2nd Resistance Point 4.19
1st Resistance Point 4.11
Last Price 4.02
1st Support Level 3.97
2nd Support Level 3.91
3rd Support Level 3.83

See More

52-Week High 7.55
Fibonacci 61.8% 5.48
Fibonacci 50% 4.84
Fibonacci 38.2% 4.19
Last Price 4.02
52-Week Low 2.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.